Literature DB >> 21050286

Effects of gut microbiota on obesity and atherosclerosis via modulation of inflammation and lipid metabolism.

R Caesar1, F Fåk, F Bäckhed.   

Abstract

Recent studies have revealed a close relationship between inflammatory and metabolic pathways, and inflammation is now recognized to have a major role in obesity and metabolic diseases such as insulin resistance and atherosclerosis. The human body is home to a large number of distinct microbial communities, with the densest population in the distal gut (the gut microbiota). Bacteria have long been known to activate inflammatory pathways, and recent data demonstrate that the gut microbiota may affect lipid metabolism and function as an environmental factor that influences the development of obesity and related diseases. Here, we review how the gut microbiota may affect metabolic diseases by activating the innate immune system.
© 2010 The Association for the Publication of the Journal of Internal Medicine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21050286     DOI: 10.1111/j.1365-2796.2010.02270.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  76 in total

Review 1.  Cardiovascular genomics: a biomarker identification pipeline.

Authors:  John H Phan; Chang F Quo; May Dongmei Wang
Journal:  IEEE Trans Inf Technol Biomed       Date:  2012-05-16

Review 2.  Gut microbiota: a new path to treat obesity.

Authors:  Giovanna Muscogiuri; Elena Cantone; Sara Cassarano; Dario Tuccinardi; Luigi Barrea; Silvia Savastano; Annamaria Colao
Journal:  Int J Obes Suppl       Date:  2019-04-12

Review 3.  Stress and obesity as risk factors in cardiovascular diseases: a neuroimmune perspective.

Authors:  Flora Ippoliti; Nicoletta Canitano; Rita Businaro
Journal:  J Neuroimmune Pharmacol       Date:  2013-01-18       Impact factor: 4.147

4.  Octreotide alleviates obesity by reducing intestinal glucose absorption and inhibiting low-grade inflammation.

Authors:  R Liu; N Wei; W Guo; O Qiang; X Li; Y Ou; W Huang; C W Tang
Journal:  Eur J Nutr       Date:  2012-07-18       Impact factor: 5.614

5.  A novel cobiotic-based preventive approach against high-fat diet-induced adiposity, nonalcoholic fatty liver and gut derangement in mice.

Authors:  D P Singh; P Khare; J Zhu; K K Kondepudi; J Singh; R K Baboota; R K Boparai; R Khardori; K Chopra; M Bishnoi
Journal:  Int J Obes (Lond)       Date:  2015-09-23       Impact factor: 5.095

Review 6.  Lipidomic profiling at the interface of metabolic surgery and cardiovascular disease.

Authors:  Ryan H Ban; Virginia Kamvissi; Klaus-Martin Schulte; Stefan Richard Bornstein; Francesco Rubino; Juergen Graessler
Journal:  Curr Atheroscler Rep       Date:  2014-11       Impact factor: 5.113

7.  Different effects of hyperlipidic diets in human lactation and adulthood: growth versus the development of obesity.

Authors:  Marià Alemany
Journal:  Reprod Biol Endocrinol       Date:  2011-07-28       Impact factor: 5.211

Review 8.  The gut microbiome as novel cardio-metabolic target: the time has come!

Authors:  Sarah Vinjé; Erik Stroes; Max Nieuwdorp; Stan L Hazen
Journal:  Eur Heart J       Date:  2013-11-11       Impact factor: 29.983

9.  The emerging relevance of the gut microbiome in cardiometabolic health.

Authors:  Martin Obin; Laurence D Parnell; Jose M Ordovas
Journal:  Curr Cardiovasc Risk Rep       Date:  2013-12-01

Review 10.  Microbiome-Mediated Effects of the Mediterranean Diet on Inflammation.

Authors:  Melisa A Bailey; Hannah D Holscher
Journal:  Adv Nutr       Date:  2018-05-01       Impact factor: 8.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.